Candida Prosthetic Valve Endocarditis Cured by Caspofungin Therapy without Valve Replacement
Clinical Infectious Diseases2005Vol. 40(9), pp. e72–e74
Citations Over TimeTop 10% of 2005 papers
Abstract
A 64-year-old woman with a mechanical mitral valve prosthesis developed late-onset Candida endocarditis. Blood cultures grew Candida glabrata and Candida krusei. Transesophageal echocardiography demonstrated vegetations on the valve. The patient was not medically fit for valve replacement, but her condition was successfully treated with 6 weeks of intravenous caspofungin therapy.
Related Papers
- → Emergence of disseminated candidiasis caused byCandida kruseiduring treatment with caspofungin: Case report and review of literature(2005)58 cited
- → Comparative In Vitro Activities of Caspofungin and Micafungin, Determined Using the Method of the European Committee on Antimicrobial Susceptibility Testing, against Yeast Isolates Obtained in France in 2005-2006(2007)48 cited
- → Comparative study of mechanical and transcatheter heart valves for aortic valve replacement(2021)1 cited
- Effect of athrombogenic therapy, especially high dose therapy of dipyridamole, after prosthetic valve replacement.(1975)
- → P1955 Killing kinetics of caspofungin and anidulafungin against Candida krusei(2007)